EatStreet, an online and mobile food ordering company, has closed a $15 million Series C funding round led by 4490 Ventures Lumia Capital. GCI Capital, MATH Venture Partners and State of Wisconsin Investment Board also participated. “We’ve exceeded all expectations in 2015 and given the fast-paced nature of the online food ordering industry, we’re thrilled to announce this most recent round of investment,” says Matt Howard, CEO and co-founder of EatStreet. “It’s unbelievable to think that just a few years ago there were three of us in a dorm room building a product that we thought would change the way people ordered food. And today, we’re processing millions of orders for customers nationwide.”
ThreatQuotient, a threat intelligence startup, has secured a $10.2 million Series A funding round led by New Enterprise Associates. Blu Venture Investors and the Center for Innovative Technology also participated. The company will use the funding to expand its global reach. “We are excited to align with ThreatQuotient because the founders built a solution to a problem they lived and breathed in security and operations centers. They have the history and experience we seek in our investments and a solid existing customer portfolio,” said NEA’s Harry Weller. “In fact, we take due diligence very seriously and throughout that process ThreatQuotient’s customer references demonstrated the company’s unique approach and technology is the type of innovation we look for in an investment.”
BrightFunnel, which provides a revenue attribution and forecasting platform for marketers, has secured $6 million in Series A funding led by Crosslink Capital. Salesforce Ventures also joined the round along with previous investors Bloomberg Beta, Karlin Ventures, and Resolute Ventures. “BrightFunnel allows marketers to finally measure the impact their campaigns are having on revenue,” said David Silverman, Partner, Crosslink Capital. “I personally invested in Omniture and see BrightFunnel poised to have a similar impact as this generation’s premier B2B marketing analytics platform.”
True North Therapeutics, a biotechnology company, has completed a $40 million Series C financing round. New Leaf Venture Partners led the round, with participation from Perceptive Advisors and Cowen Private Investments, as well as existing investors Kleiner Perkins Caufield & Byers, MPM Capital, OrbiMed, SR One, and Baxalta Ventures. “We are delighted by the strong support and recognition we received in this Series C financing and to have expanded our list of recognized life science investors to include New Leaf Venture Partners as well as Perceptive Advisors, and Cowen Private Investments,” said Nancy Stagliano, PhD, Chief Executive Officer of True North. “We look forward to the valuable perspectives Isaac will bring to True North’s board as we rapidly execute on our clinical program for TNT009 in Cold Agglutinin Disease and to make a difference in this neglected patient population.”